Keep pulling the thread on Jennifer Doudna.
Jennifer Doudna was awarded the 2020 Nobel Prize in Chemistry for her role in developing the CRISPR-Cas9 genome engineering technology.
CRISPR technology is being used in clinical trials to correct the mutations responsible for sickle cell disease.
CRISPR technology is being used in clinical trials to correct a protein-aggregating liver disease by editing genes in the liver.
At the end of 2018, an announcement was made that CRISPR had been used to edit human embryos, which resulted in a pregnancy and the birth of twins with edited genes.
A major challenge for CRISPR technology is the delivery of editing tools into the correct cells or tissues.
A significant challenge in the field of genome editing is ensuring the precision of CRISPR, specifically the ability to precisely dictate the exact change made to the DNA.
The Innovative Genomics Institute, in a three-way partnership with the University of California, Berkeley, UCSF, and UCLA, is conducting an FDA-approved Phase 1 clinical trial for a CRISPR-based therapy for sickle cell disease.
In 2014, Jennifer Doudna and Jonathan Wiseman co-founded the nonprofit Innovative Genomics Institute.
The mission of the Innovative Genomics Institute is to develop genome engineering as a tool to treat human diseases and end hunger.
CRISPR is an adaptive immune system in bacteria that uses RNA molecules, transcribed from viral DNA, to find and destroy the genetic material of invading viruses.
The CRISPR-Cas9 protein cuts DNA molecules using an RNA guide.
Jennifer Doudna predicts that CRISPR technology will be transformative in agriculture by enabling genetic changes in plants and their supporting microorganisms.